XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:      
Net income (loss) $ 5,710,913 $ (20,982,894)  
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Depreciation and amortization 4,082 4,081  
Amortization of capitalized software 17,027 19,155  
Stock-based compensation expense 1,075,875 1,357,317  
Non-cash interest expense associated with the sale of future royalties 4,562,223 6,092,795  
Remeasurement of liability related to sale of future royalties (26,579,046)    
Changes in operating assets and liabilities      
Refundable regulatory fee   3,117,218  
Prepaid expenses and other current assets (317,480) (373,103)  
Accounts payable (1,252,128) 425,403  
Accrued expenses and other current liabilities 2,394,751 1,546,681  
Net cash used in operating activities (14,383,783) (8,793,347)  
Cash flows from investing activities:      
Net cash provided by investing activities 0 0  
Cash flows from financing activities:      
Proceeds from sales of common stock and warrants in private placement   19,999,994  
Costs paid in connection with private placements   (396,293)  
Net cash provided by financing activities   19,603,701  
Net decrease in cash, cash equivalents and restricted cash (14,383,783) 10,810,354  
Cash, cash equivalents and restricted cash      
Beginning of period 41,012,575 36,193,606 $ 36,193,606
End of period 26,628,792 47,003,960 41,012,575
Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets      
Cash and cash equivalents 26,528,792 46,903,960 40,912,575
Restricted cash 100,000 100,000 $ 100,000
Total cash, cash equivalents and restricted cash $ 26,628,792 $ 47,003,960